Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Scynexis Inc (SCYX)

Scynexis Inc (SCYX)
0.8600 x 5 0.9750 x 5
Post-market by (Cboe BZX)
0.9043 -0.0083 (-0.91%) 04/17/25 [NASDAQ]
0.8600 x 5 0.9750 x 5
Post-market 0.9043 unch (unch) 16:00 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.8901
Day High
0.9750
Open 0.9445
Previous Close 0.9126 0.9126
Volume 88,100 88,100
Avg Vol 94,490 94,490
Stochastic %K 64.11% 64.11%
Weighted Alpha -60.08 -60.08
5-Day Change +0.0243 (+2.76%) +0.0243 (+2.76%)
52-Week Range 0.7284 - 3.0700 0.7284 - 3.0700
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,251
  • Shares Outstanding, K 38,981
  • Annual Sales, $ 3,750 K
  • Annual Income, $ -21,290 K
  • EBIT $ -37 M
  • EBITDA $ -35 M
  • 60-Month Beta 1.71
  • Price/Sales 9.50
  • Price/Cash Flow N/A
  • Price/Book 0.63
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.60
  • Most Recent Earnings $-0.09 on 03/12/25
  • Next Earnings Date 05/14/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 408.40% ( -272.03%)
  • Historical Volatility 84.44%
  • IV Percentile 87%
  • IV Rank 43.51%
  • IV High 923.84% on 06/24/24
  • IV Low 11.47% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,643
  • Open Int (30-Day) 1,785

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.23
  • Number of Estimates 1
  • High Estimate -0.23
  • Low Estimate -0.23
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -53.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7284 +24.15%
on 04/07/25
Period Open: 1.1000
1.0806 -16.32%
on 03/18/25
-0.1957 (-17.79%)
since 03/17/25
3-Month
0.7284 +24.15%
on 04/07/25
Period Open: 1.1200
1.2450 -27.37%
on 02/11/25
-0.2157 (-19.26%)
since 01/17/25
52-Week
0.7284 +24.15%
on 04/07/25
Period Open: 1.4200
3.0700 -70.54%
on 05/20/24
-0.5157 (-36.32%)
since 04/17/24

Most Recent Stories

More News
SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

SCYX : 0.9043 (-0.91%)
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

SCYX : 0.9043 (-0.91%)
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYX : 0.9043 (-0.91%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 0.9043 (-0.91%)
SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SCYX : 0.9043 (-0.91%)
SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit

SCYX : 0.9043 (-0.91%)
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024

SCYX : 0.9043 (-0.91%)
Scynexis: Q2 Earnings Snapshot

Scynexis: Q2 Earnings Snapshot

SCYX : 0.9043 (-0.91%)
Scynexis: Q1 Earnings Snapshot

Scynexis: Q1 Earnings Snapshot

SCYX : 0.9043 (-0.91%)
Scynexis: Q3 Earnings Snapshot

Scynexis: Q3 Earnings Snapshot

SCYX : 0.9043 (-0.91%)

Business Summary

SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening...

See More

Key Turning Points

3rd Resistance Point 1.0411
2nd Resistance Point 1.0080
1st Resistance Point 0.9562
Last Price 0.9043
1st Support Level 0.8713
2nd Support Level 0.8382
3rd Support Level 0.7864

See More

52-Week High 3.0700
Fibonacci 61.8% 2.1755
Fibonacci 50% 1.8992
Fibonacci 38.2% 1.6229
Last Price 0.9043
52-Week Low 0.7284

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro